Abstract
More than 100 years ago, German physician Paul Ehrlich first proposed the concept of selectively delivering “magic bullets” to tumors through targeting agents. The targeting therapy with antibody-drug conjugates (ADCs) and peptide-drug conjugate (PDCs), which are usually composed of monoclonal antibodies or peptides, toxic payloads and cleavage/ noncleavage linkers, has been extensively studied for decades. The conjugates enable selective delivery of cytotoxic payloads to target cells, which results in improved efficacy, reduced systemic toxicity and improved pharmacokinetics (PK)/pharmacodynamics (PD) compared with traditional chemotherapy. PDC and ADC share similar concept, but with vastly different structures and properties. Humanized antibodies introduce high specificity and prolonged half-life, while small molecule weight peptides exhibit higher drug loading and enhanced tissue penetration capacity, and the flexible linear or cyclic peptides are also modified more easily. In this review, the principles of design, synthesis approaches and the latest advances of PDCs are summarized.
Keywords: Peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs), peptide, linker, payloads, drug design.
Current Medicinal Chemistry
Title:Peptide-Drug Conjugate: A Novel Drug Design Approach
Volume: 24 Issue: 31
Author(s): Liang Ma, Chao Wang, Zihao He, Biao Cheng, Ling Zheng and Kun Huang*
Affiliation:
- Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan,China
Keywords: Peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs), peptide, linker, payloads, drug design.
Abstract: More than 100 years ago, German physician Paul Ehrlich first proposed the concept of selectively delivering “magic bullets” to tumors through targeting agents. The targeting therapy with antibody-drug conjugates (ADCs) and peptide-drug conjugate (PDCs), which are usually composed of monoclonal antibodies or peptides, toxic payloads and cleavage/ noncleavage linkers, has been extensively studied for decades. The conjugates enable selective delivery of cytotoxic payloads to target cells, which results in improved efficacy, reduced systemic toxicity and improved pharmacokinetics (PK)/pharmacodynamics (PD) compared with traditional chemotherapy. PDC and ADC share similar concept, but with vastly different structures and properties. Humanized antibodies introduce high specificity and prolonged half-life, while small molecule weight peptides exhibit higher drug loading and enhanced tissue penetration capacity, and the flexible linear or cyclic peptides are also modified more easily. In this review, the principles of design, synthesis approaches and the latest advances of PDCs are summarized.
Export Options
About this article
Cite this article as:
Ma Liang, Wang Chao, He Zihao, Cheng Biao, Zheng Ling and Huang Kun*, Peptide-Drug Conjugate: A Novel Drug Design Approach, Current Medicinal Chemistry 2017; 24 (31) . https://dx.doi.org/10.2174/0929867324666170404142840
DOI https://dx.doi.org/10.2174/0929867324666170404142840 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MALDI Mass Spectrometry Imaging, from its Origins up to Today: The State of the Art
Combinatorial Chemistry & High Throughput Screening Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Diverse Models for the Prediction of Dual mTOR and PI3Kα Inhibitory Activities of Substituted 4-morpholinopyrrolopyrimidines
Letters in Drug Design & Discovery Chemotherapeutic Targeting of Cell Death Pathways
Anti-Cancer Agents in Medicinal Chemistry Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Activation of Sphingosine Kinase-1 in Cancer: Implications for Therapeutic Targeting
Current Molecular Pharmacology From TGF-β to Cancer Therapy
Current Drug Targets Anticancer Natural Products with Collateral Sensitivity: A Review
Mini-Reviews in Medicinal Chemistry Structural Basis and Therapeutic Implication of the Interaction of CCN Proteins with Glycoconjugates
Current Pharmaceutical Design Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry
Current Metabolomics Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology Sigma Receptors and Cocaine Abuse
Current Topics in Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Undermining Tumor Angiogenesis by Gene Therapy: An Emerging Field
Current Gene Therapy Regulation of Tumor Immune Microenvironment by Sphingolipids and Lysophosphatidic Acid
Current Drug Targets Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience